Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1733
Abstract: Although the prognosis of core‐binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no… read more here.
Keywords: binding factor; scoring system; myeloid leukemia; core binding ... See more keywords
Expression dynamics of lymphoid enhancer‐binding factor 1 in terminal Schwann cells, dermal papilla, and interfollicular epidermis
Sign Up to like & getrecommendations! Published in 2022 at "Developmental Dynamics"
DOI: 10.1002/dvdy.562
Abstract: Transcription factor lymphoid enhancer‐binding factor 1 (LEF1) is a downstream mediator of the Wnt/β‐catenin signaling pathway. It is expressed in dermal papilla and surrounding cells in the hair follicle, promoting cell proliferation, and differentiation. read more here.
Keywords: binding factor; lymphoid enhancer; dermal papilla; factor ... See more keywords
Backbone and side chain NMR assignments for the ribosome binding factor A (RbfA) from Staphylococcus aureus
Sign Up to like & getrecommendations! Published in 2019 at "Biomolecular NMR Assignments"
DOI: 10.1007/s12104-018-9845-0
Abstract: Ribosome binding factor A (RbfA) is a 14.9 kDa adaptive protein of cold shock, which is important for bacterial growth at low temperatures. RbfA can bind to the free 30S ribosomal subunit and interacts with the… read more here.
Keywords: factor rbfa; binding factor; topology; rbfa ... See more keywords
Interleukin-2 enhancer binding factor 2 (ILF2) in Pacific white shrimp (Litopenaeus vannamei): Alternatively spliced isoforms with different responses in the immune defenses against Vibrio infection.
Sign Up to like & getrecommendations! Published in 2020 at "Developmental and comparative immunology"
DOI: 10.1016/j.dci.2020.103975
Abstract: Alternative splicing is an essential molecular mechanism that increase the protein diversity of a species to regulate important biological processes. As a transcription factor, Interleukin-2 enhancer binding factor 2 (ILF2) regulates the functions of interleukin-2… read more here.
Keywords: binding factor; interleukin enhancer; enhancer binding; shrimp ... See more keywords
Identification of novel C-repeat binding factor (CBF) genes in rye (Secale cereale L.) and expression studies.
Sign Up to like & getrecommendations! Published in 2019 at "Gene"
DOI: 10.1016/j.gene.2018.10.055
Abstract: Although rye is one of the most cold-tolerant species among temperate cereals, its huge and complex genome has prevented us from identifying agronomically useful genes. However, advances in high-throughput sequencing technology are making it increasingly… read more here.
Keywords: cbf genes; binding factor; cbf; rye ... See more keywords
Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0164-3
Abstract: Minimal residual core binding factor AMLs by real time quantitative PCR—initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30:389–95. 8. Weisser M,… read more here.
Keywords: cell; minimal residual; binding factor; core binding ... See more keywords
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Sign Up to like & getrecommendations! Published in 2021 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00503-6
Abstract: Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved… read more here.
Keywords: factor acute; binding factor; myelogenous leukemia; core binding ... See more keywords
Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Chemotherapy"
DOI: 10.1159/000512314
Abstract: Although core-binding factor AML (CBF-AML) has a favorable outcome, disease relapses occur in up to 35% of patients. Minimal residual disease (MRD) monitoring is one of the important tools to enable us to identify patients… read more here.
Keywords: binding factor; minimal residual; maintenance; disease ... See more keywords
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020008971
Abstract: The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of crucial transcription factors. One of the key master regulators in the hematopoietic systems is… read more here.
Keywords: transcription; binding factor; antisense promoter; core binding ... See more keywords
Core Binding Factor β Expression in Ovarian Granulosa Cells Is Essential for Female Fertility.
Sign Up to like & getrecommendations! Published in 2018 at "Endocrinology"
DOI: 10.1210/en.2018-00011
Abstract: Core binding factor β (CBFβ) is a non-DNA-binding partner of all RUNX proteins and critical for transcription activity of CBF transcription factors (RUNXs/CBFβ). In the ovary, the expression of Runx1 and Runx2 is highly induced… read more here.
Keywords: granulosa cells; binding factor; expression; core binding ... See more keywords
Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Haematologica"
DOI: 10.3324/haematol.2019.222810
Abstract: Core binding factor acute myeloid leukemia (AML) comprises two subtypes with distinct cytogenetic abnormalities of either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22). Since long-term response to chemotherapy in these leukemias is relatively good, allogeneic hematopoietic stem cell transplantation… read more here.
Keywords: factor acute; binding factor; relapse; transplantation ... See more keywords